MCID: DRR001
MIFTS: 55

Diarrhea

Categories: Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases

Aliases & Classifications for Diarrhea

MalaCards integrated aliases for Diarrhea:

Name: Diarrhea 12 29 6 42 15 39
Diarrhoea 12 15
Diarrhea of Presumed Infectious Origin 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13250
ICD9CM 34 009.2
MeSH 43 D004403
SNOMED-CT 67 19213003
UMLS 71 C0013369

Summaries for Diarrhea

MedlinePlus : 42 What is diarrhea? Diarrhea is loose, watery stools (bowel movements). You have diarrhea if you have loose stools three or more times in one day. Acute diarrhea is diarrhea that lasts a short time. It is a common problem. It usually lasts about one or two days, but it may last longer. Then it goes away on its own. Diarrhea lasting more than a few days may be a sign of a more serious problem. Chronic diarrhea -- diarrhea that lasts at least four weeks -- can be a symptom of a chronic disease. Chronic diarrhea symptoms may be continual, or they may come and go. What causes diarrhea? The most common causes of diarrhea include Bacteria from contaminated food or water Viruses such as the flu, norovirus, or rotavirus . Rotavirus is the most common cause of acute diarrhea in children. Parasites, which are tiny organisms found in contaminated food or water Medicines such as antibiotics, cancer drugs, and antacids that contain magnesium Food intolerances and sensitivities, which are problems digesting certain ingredients or foods. An example is lactose intolerance. Diseases that affect the stomach, small intestine, or colon, such as Crohn's disease Problems with how the colon functions, such as irritable bowel syndrome Some people also get diarrhea after stomach surgery, because sometimes the surgeries can cause food to move through your digestive system more quickly. Sometimes no cause can be found. If your diarrhea goes away within a few days, finding the cause is usually not necessary. Who is at risk for diarrhea? People of all ages can get diarrhea. On average, adults In the United States have acute diarrhea once a year. Young children have it an average of twice a year. People who visit developing countries are at risk for traveler's diarrhea. It is caused by consuming contaminated food or water. What other symptoms might I have with diarrhea? Other possible symptoms of diarrhea include Cramps or pain in the abdomen An urgent need to use the bathroom Loss of bowel control If a virus or bacteria is the cause of your diarrhea, you may also have a fever, chills, and bloody stools. Diarrhea can cause dehydration, which means that your body does not have enough fluid to work properly. Dehydration can be serious, especially for children, older adults, and people with weakened immune systems. When do I need to see a health care provider for diarrhea? Although it is usually not harmful, diarrhea can become dangerous or signal a more serious problem. Contact your health care provider if you have Signs of dehydration Diarrhea for more than 2 days, if you are an adult. For children, contact the provider if it lasts more than 24 hours. Severe pain in your abdomen or rectum (for adults) A fever of 102 degrees or higher Stools containing blood or pus Stools that are black and tarry If children have diarrhea, parents or caregivers should not hesitate to call a health care provider. Diarrhea can be especially dangerous in newborns and infants. How is the cause of diarrhea diagnosed? To find the cause of diarrhea, your health care provider may Do a physical exam Ask about any medicines you are taking Test your stool or blood to look for bacteria, parasites, or other signs of disease or infection Ask you to stop eating certain foods to see whether your diarrhea goes away If you have chronic diarrhea, your health care provider may perform other tests to look for signs of disease. What are the treatments for diarrhea? Diarrhea is treated by replacing lost fluids and electrolytes to prevent dehydration. Depending on the cause of the problem, you may need medicines to stop the diarrhea or treat an infection. Adults with diarrhea should drink water, fruit juices, sports drinks, sodas without caffeine, and salty broths. As your symptoms improve, you can eat soft, bland food. Children with diarrhea should be given oral rehydration solutions to replace lost fluids and electrolytes. Can diarrhea be prevented? Two types of diarrhea can be prevented - rotavirus diarrhea and traveler's diarrhea. There are vaccines for rotavirus. They are given to babies in two or three doses. You can help prevent traveler's diarrhea by being careful about what you eat and drink when you are in developing countries: Use only bottled or purified water for drinking, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diarrhea, also known as diarrhoea, is related to diarrhea 5, with tufting enteropathy, congenital and diarrhea 2, with microvillus atrophy. An important gene associated with Diarrhea is WNT2B (Wnt Family Member 2B), and among its related pathways/superpathways is Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers. The drugs Pinaverium and Carboprost tromethamine have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and breast, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Disease Ontology : 12 A gastrointestinal system disease described as the condition of having frequent loose or liquid bowel movements. Acute diarrhea is a common cause of death in developing countries and the second most common cause of infant deaths worldwide. The loss of fluids through diarrhea can cause severe dehydration which is one cause of death in diarrhea sufferers. Along with water, sufferers also lose dangerous amounts of important salts, electrolytes, and other nutrients. There are at least four types of diarrhea: secretory diarrhea, osmotic diarrhea, motility-related diarrhea, and inflammatory diarrhea.

Wikipedia : 74 Diarrhea, also spelled diarrhoea, is the condition of having at least three loose, liquid, or watery... more...

Related Diseases for Diarrhea

Diseases in the Diarrhea family:

Diarrhea 6 Diarrhea 9
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1375)
# Related Disease Score Top Affiliating Genes
1 diarrhea 5, with tufting enteropathy, congenital 35.4 TTC37 SPINT2 SLC9A3 SLC26A3 NEUROG3 MYO5B
2 diarrhea 2, with microvillus atrophy 35.4 TTC37 SLC9A3 SLC26A3 MYO5B
3 diarrhea 3, secretory sodium, congenital, with or without other congenital anomalies 35.3 SPINT2 SLC9A3 GUCY2C
4 diarrhea 4, malabsorptive, congenital 35.2 TTC37 SPINT2 NEUROG3 MYO5B
5 secretory diarrhea 35.1 SST SPINT2 SLC9A3 SLC26A3 MYO5B GUCY2C
6 diarrhea 1, secretory chloride, congenital 35.1 SLC9A3 SLC26A3
7 congenital diarrhea 35.1 TTC37 SPINT2 SLC9A3 SLC26A3 NEUROG3 MYO5B
8 osmotic diarrhea 35.0 WNT2B SLC9A3 SLC26A3
9 diarrhea 8, secretory sodium, congenital 35.0 SLC9A3 MYO5B
10 inflammatory diarrhea 34.8 SLC9A3 SLC26A3
11 short bowel syndrome 33.4 SST SLC9A3 CCK
12 bile acid malabsorption, primary 33.3 TMPRSS15 SST CCK
13 enterokinase deficiency 33.1 TMPRSS15 CCK
14 constipation 32.3 SST GUCY2C CYP3A4 CCK
15 dumping syndrome 31.6 SST SI CCK
16 ileus 31.6 SST SLC9A3 GUCY2C CCK
17 diabetes mellitus, type i 31.0 SST SI NEUROG3 FOXP3 CD40LG
18 cholelithiasis 30.9 SST CD40LG CCK
19 acute pancreatitis 30.9 TMPRSS15 SST CCK
20 gastroparesis 30.8 SST CYP3A4 CCK
21 biliary dyskinesia 30.7 SST CCK
22 cerebral lymphoma 30.6 SST CD40LG
23 postgastrectomy syndrome 30.5 SST SI
24 cholecystolithiasis 30.4 SST CCK
25 proprotein convertase 1/3 deficiency 30.4 NEUROG3 MYO5B
26 bacterial conjunctivitis 30.4 TTC37 CD40LG
27 active peptic ulcer disease 30.3 SST CYP3A4
28 meconium ileus 30.1 SLC9A3 GUCY2C
29 congenital chloride diarrhea 12.6
30 diarrhea 6 12.6
31 acute diarrhea 12.6
32 diarrhea 11, malabsorptive, congenital 12.6
33 diarrhea 9 12.5
34 chronic diarrhea due to guanylate cyclase 2c overactivity 12.5
35 diarrhea 10, protein-losing enteropathy type 12.4
36 trichohepatoenteric syndrome 1 12.4
37 congenital diarrhea 7 with exudative enteropathy 12.4
38 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 12.4
39 diarrhea 7, protein-losing enteropathy type 12.3
40 motility-related diarrhea 12.3
41 functional diarrhea 12.3
42 diarrhea, chronic, with villous atrophy 12.3
43 secretory diarrhea, myopathy, and deafness 12.3
44 diarrhea, glucose-stimulated secretory, with common variable immunodeficiency 12.2
45 dysentery 12.2
46 intractable diarrhea-choanal atresia-eye anomalies syndrome 12.1
47 genetic intractable diarrhea of infancy 12.1
48 syndromic congenital sodium diarrhea 12.1
49 chronic diarrhea due to glucoamylase deficiency 12.1
50 hemolytic uremic syndrome, atypical 1 12.0

Graphical network of the top 20 diseases related to Diarrhea:



Diseases related to Diarrhea

Symptoms & Phenotypes for Diarrhea

MGI Mouse Phenotypes related to Diarrhea:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 CCK CD40LG DGAT1 EPCAM FOXP3 GUCY2C
2 digestive/alimentary MP:0005381 9.91 DGAT1 EPCAM FOXP3 GUCY2C MYO5B NEUROG3
3 no phenotypic analysis MP:0003012 9.5 CCK EPCAM FOXP3 NEUROG3 NMNAT1 SST
4 renal/urinary system MP:0005367 9.17 CCK CD40LG FOXP3 NEUROG3 SGSH SLC9A3

Drugs & Therapeutics for Diarrhea

Drugs for Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 942)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pinaverium Approved Phase 4 59995-65-2
2
Carboprost tromethamine Approved Phase 4 58551-69-2 5284525 35023177
3
Cobicistat Approved Phase 4 1004316-88-4
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
6
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
7
Rilpivirine Approved Phase 4 500287-72-9
8
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
9
Ondansetron Approved Phase 4 99614-02-5 4595
10
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
11
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
12
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
16
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
17 Strawberry Approved Phase 4
18
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
19
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
20
Calcium carbonate Approved, Investigational Phase 4 471-34-1
21
Cefpirome Approved Phase 4 84957-29-9 5479539
22
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
23
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
24
Sulfamethoxazole Approved Phase 4 723-46-6 5329
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Lumefantrine Approved Phase 4 82186-77-4 6437380
27
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
28
Alverine Approved, Investigational Phase 4 150-59-4 3678
29
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
30
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
31
Dimenhydrinate Approved Phase 4 523-87-5 441281
32
Linaclotide Approved Phase 4 851199-59-2 65351
33
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
34
Aminophylline Approved Phase 4 317-34-0 9433
35
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
36
Ibuprofen Approved Phase 4 15687-27-1 3672
37
Insulin aspart Approved Phase 4 116094-23-6 16132418
38
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
39
Gliclazide Approved Phase 4 21187-98-4 3475
40
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
41
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
42
Polyestradiol phosphate Approved Phase 4 28014-46-2
43
Methylene blue Approved, Investigational Phase 4 61-73-4
44
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
45
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
46
Sorbitol Approved Phase 4 50-70-4 5780
47
Pantoprazole Approved Phase 4 102625-70-7 4679
48
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
49
Ledipasvir Approved Phase 4 1256388-51-8 67505836
50
Sofosbuvir Approved Phase 4 1190307-88-0 45375808

Interventional clinical trials:

(show top 50) (show all 2595)
# Name Status NCT ID Phase Drugs
1 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
2 Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae Unknown status NCT02121145 Phase 4
3 The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial Unknown status NCT01792739 Phase 4 Lactobacillus casei variety rhamnosus granules;Placebo
4 Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome Unknown status NCT03557788 Phase 4 Rifaximin Oral Tablet
5 Bacillus Particles Prevent More Children's Antibiotic-associated Diarrhea (AAD), Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT02993419 Phase 4 Bacillus licheniformis Intervention
6 Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle Unknown status NCT01469273 Phase 4 Mutaflor® Suspension
7 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
8 Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
9 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
10 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
11 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
12 Phase 4 Study of Effects of Dexmedetomidine on Prevention of Side Effects of Hemabate in Cesarean Section Patients Unknown status NCT02220361 Phase 4 placebo;low dose dexmedetomidine;high dose dexmedetomidine
13 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
14 Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
15 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
16 Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
17 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
18 Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery Unknown status NCT02849483 Phase 4 Ramosetron;Normal saline
19 Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
20 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
21 Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study Unknown status NCT02508142 Phase 4 Hyoscine-N-Butylbromide
22 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
23 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
24 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
25 The Hypotensive Effect of Simvastatin in Hypertensive Patients: a Placebo-controlled Randomized Clinical Trial With 24-h Ambulatory Blood Pressure Monitoring Unknown status NCT02072382 Phase 4 Metformin;Placebo
26 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
27 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
28 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
29 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
30 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
31 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
32 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
33 Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range Unknown status NCT01424241 Phase 4 Sandostatin LAR
34 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
35 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
36 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
37 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
38 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
39 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
40 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
41 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Unknown status NCT03519568 Phase 4
42 Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomised, Double Blind, Placebo Controlled, Parallel Groups Study. Completed NCT00276328 Phase 4 Diosmectite (Smecta®)
43 Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomized, Double Blind Placebo Controlled, Parallel, Groups Study Completed NCT02704091 Phase 4 Smecta;Smecta placebo
44 Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). Completed NCT01316718 Phase 4 Mesalazine;Placebo
45 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder" Completed NCT00745004 Phase 4 Ondansetron;Placebo
46 Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea Completed NCT03059537 Phase 4 Oral chenodeoxycholic acid stimulation
47 A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
48 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
49 A Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack(Comprising of Low Osmolality ORS, Zinc Tablets, Water Purification Tablets and Pictorial Chart) on Childhood Diarrhea. Completed NCT00942812 Phase 4
50 Introduction of New Hypo-osmolar ORS Into Routine Use in the Management of Diarrhoeal Disease: a Phase IV Clinical Surveillance. Completed NCT00244777 Phase 4 Hypo-osmolar ORS

Search NIH Clinical Center for Diarrhea

Genetic Tests for Diarrhea

Genetic tests related to Diarrhea:

# Genetic test Affiliating Genes
1 Diarrhea 29

Anatomical Context for Diarrhea

MalaCards organs/tissues related to Diarrhea:

40
Colon, Testes, Breast, Lung, Small Intestine, Liver, Kidney

Publications for Diarrhea

Articles related to Diarrhea:

(show top 50) (show all 56636)
# Title Authors PMID Year
1
Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. 61 42
32102928 2020
2
The digestive system and the COVID-19. 42 61
32515381 2020
3
Drugs for Irritable Bowel Syndrome. 42
32324172 2020
4
Immunization with porcine epidemic diarrhea virus harbouring Fc domain of IgG enhances antibody production in pigs. 61
32448096 2020
5
Establishment of stable Vero cell lines expressing TMPRSS2 and MSPL: A useful tool for propagating porcine epidemic diarrhea virus in the absence of exogenous trypsin. 61
32471322 2020
6
Interplay between enterohaemorrhagic Escherichia coli and nitric oxide during the infectious process. 61
32459575 2020
7
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. 61
31862249 2020
8
Bacillus cereus spores and toxins - The potential role of biofilms. 61
32336372 2020
9
Antiviral activity against porcine epidemic diarrhea virus of Pogostemon cablin polysaccharide. 61
32450234 2020
10
Genus Ziziphus: A comprehensive review on ethnopharmacological, phytochemical and pharmacological properties. 61
32450235 2020
11
Caspase-mediated cleavage of nucleocapsid protein of a protease-independent porcine epidemic diarrhea virus strain. 61
32482590 2020
12
Antiviral activity of native banana lectin against bovine viral diarrhea virus and bovine alphaherpesvirus type 1. 61
32335107 2020
13
Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): An update three years after its discovery. 61
32482591 2020
14
The NADL strain of bovine viral diarrhea virus induces the secretion of IL-1β through caspase 1 in bovine macrophages. 61
32335355 2020
15
Virome diversity analysis reveals novel enteroviruses and a human picobirnavirus in stool samples from African green monkeys with diarrhea. 61
32165243 2020
16
Impact of a natural versus commercial enteral-feeding on the occurrence of diarrhea in critically ill cardiac surgery patients. A retrospective cohort study. 61
32502821 2020
17
Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 61
32369658 2020
18
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. 61
32247004 2020
19
'Immunising' physicians against availability bias in diagnostic reasoning: a randomised controlled experiment. 61
31988257 2020
20
Hypocalcaemia in children hospitalised for diarrhoea was associated with a higher death rate than those without hypocalcaemia. 61
31901173 2020
21
Serological evidence for exposure to bovine viral diarrhoea virus in sheep co-grazed with beef cattle in New Zealand. 61
31852409 2020
22
Workflow optimization for syndromic diarrhea diagnosis using the molecular Seegene Allplex™ GI-Bacteria(I) assay. 61
32026192 2020
23
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. 61
32470848 2020
24
Death of a neonatal lamb due to Clostridium perfringens type B in New Zealand. 61
31852382 2020
25
Egested Feces Revealed Massive Protein Loss in 99mTc-HSA-D Scintigraphy. 61
32433159 2020
26
EuNPs-mAb fluorescent probe based immunochromatographic strip for rapid and sensitive detection of porcine epidemic diarrhea virus. 61
32278431 2020
27
Breastfeeding initiation or duration and longitudinal patterns of infections up to 2 years and skin rash and respiratory symptoms up to 8 years in the EDEN mother-child cohort. 61
31970921 2020
28
The ethnopharmacology, phytochemistry, pharmacology and toxicology of genus Albizia: A review. 61
32278761 2020
29
Pet dogs potential transmitters of pathogenic Escherichia coli with resistance to antimicrobials. 61
32076735 2020
30
Randomised trial showed that rapid rehydration of severely malnourished children with dehydrating diarrhoea was as safe and effective as slow rehydration. 61
31828841 2020
31
A critical literature review on the use of bellyboard devices to control small bowel dose for pelvic radiotherapy. 61
32518531 2020
32
Maternal dietary uridine supplementation reduces diarrhea incidence in piglets by regulating the intestinal mucosal barrier and cytokine profiles. 61
32248539 2020
33
Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. 61
32387182 2020
34
Development of a quantitative risk assessment of bovine viral diarrhea virus and bovine herpesvirus-1 introduction in dairy cattle herds to improve biosecurity. 61
32359990 2020
35
microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB. 61
32187820 2020
36
Effects of different types of zinc supplement on the growth, incidence of diarrhea, immune function, and rectal microbiota of newborn dairy calves. 61
32307167 2020
37
Prevalence of bovine viral diarrhea virus (BVDV) in yaks between 1987 and 2019 in mainland China: A systematic review and meta-analysis. 61
32272215 2020
38
Prevalence of undernutrition in Bangladeshi children. 61
31658911 2020
39
Small Flocks Show Higher Levels of Welfare in Mexican Semi-Intensive Sheep Farming Systems. 61
31169027 2020
40
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM. 61
32306039 2020
41
Species and genotypes causing human cryptosporidiosis in New Zealand. 61
32494897 2020
42
Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. 61
32077218 2020
43
Examining which clinicians provide admission hospital care in a high mortality setting and their adherence to guidelines: an observational study in 13 hospitals. 61
32169853 2020
44
Giardia and Cryptosporidium infections in Danish cats: risk factors and zoonotic potential. 61
32451716 2020
45
Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. 61
32462777 2020
46
Detection and Characterization of New Coronavirus in Bottlenose Dolphin, United States, 2019. 61
32568058 2020
47
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. 61
32553146 2020
48
Clinical Insights into the Gastrointestinal Manifestations of COVID-19. 61
32447742 2020
49
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. 61
32278065 2020
50
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. 61
32405603 2020

Variations for Diarrhea

ClinVar genetic disease variations for Diarrhea:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WNT2B NM_024494.3(WNT2B):c.205C>T (p.Arg69Ter)SNV Pathogenic 545432 rs370244148 1:113057518-113057518 1:112514896-112514896
2 SGSH NM_000199.5(SGSH):c.892T>C (p.Ser298Pro)SNV Pathogenic 30459 rs138504221 17:78185927-78185927 17:80212128-80212128
3 NMNAT1 NM_022787.4(NMNAT1):c.769G>A (p.Glu257Lys)SNV Pathogenic 37134 rs150726175 1:10042688-10042688 1:9982630-9982630
4 SGSH NM_000199.5(SGSH):c.1272_1282del (p.Tyr424_Arg428delinsTer)deletion Pathogenic/Likely pathogenic 287037 rs752914124 17:78184478-78184488 17:80210679-80210689
5 RASL12 , SLC51B NM_178859.4(SLC51B):c.84del (p.Arg29fs)deletion Likely pathogenic 804474 15:65342421-65342421 15:65050083-65050083
6 OCA2 NM_000275.3(OCA2):c.2020C>G (p.Leu674Val)SNV Conflicting interpretations of pathogenicity 194918 rs371412500 15:28171332-28171332 15:27926186-27926186

Expression for Diarrhea

Search GEO for disease gene expression data for Diarrhea.

Pathways for Diarrhea

Pathways related to Diarrhea according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.92 WNT2B NEUROG3 EPCAM

GO Terms for Diarrhea

Cellular components related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.26 SLC9A3 SLC26A3 SI EPCAM
2 brush border GO:0005903 8.92 TMPRSS15 SLC9A3 SI MME

Biological processes related to Diarrhea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-4 production GO:0032753 8.96 FOXP3 CD40LG
2 digestion GO:0007586 8.8 SST GUCY2C CCK

Sources for Diarrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....